Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1995 1
1999 2
2002 1
2003 1
2005 1
2006 1
2009 1
2011 2
2013 1
2014 2
2015 2
2017 1
2018 1
2019 1
2020 2
2021 3
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Advances in the Treatment of Hairy Cell Leukemia Variant.
Tran J, Gaulin C, Tallman MS. Tran J, et al. Curr Treat Options Oncol. 2022 Jan;23(1):99-116. doi: 10.1007/s11864-021-00927-z. Epub 2022 Feb 18. Curr Treat Options Oncol. 2022. PMID: 35178674 Review.
HCL-V is more aggressive in nature, has a higher tendency to be refractory to conventional purine analog pharmacotherapies, and leads to a poorer prognosis. Hence, these differing features bring paramount importance to the diagnosis and management of HCL-V. While there is …
HCL-V is more aggressive in nature, has a higher tendency to be refractory to conventional purine analog pharmacotherapies, and leads to a p …
Hairy cell leukemia: Update on molecular profiling and therapeutic advances.
Grever MR, Blachly JS, Andritsos LA. Grever MR, et al. Blood Rev. 2014 Sep;28(5):197-203. doi: 10.1016/j.blre.2014.06.003. Epub 2014 Jul 11. Blood Rev. 2014. PMID: 25110197 Free article. Review.
Over the past three decades, tremendous progress in both diagnostic and prognostic clarification has been accompanied by therapeutic advances in classical HCL. ...
Over the past three decades, tremendous progress in both diagnostic and prognostic clarification has been accompanied by therapeutic …
Management of hairy cell leukemia variant.
Robak T. Robak T. Leuk Lymphoma. 2011 Jun;52 Suppl 2:53-6. doi: 10.3109/10428194.2011.566392. Leuk Lymphoma. 2011. PMID: 21599606 Review.
Hairy cell leukemia variant (HCL-V) is now included in the World Health Organization (WHO) classification as a provisional entity and is no longer considered to be biologically related to classic HCL (HCL-C). The clinical course of HCL-V is variable but usually more aggres …
Hairy cell leukemia variant (HCL-V) is now included in the World Health Organization (WHO) classification as a provisional entity and is no …
Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience.
Angelova EA, Medeiros LJ, Wang W, Muzzafar T, Lu X, Khoury JD, Ravandi F, Patel KP, Hu Z, Kanagal-Shamanna R. Angelova EA, et al. Mod Pathol. 2018 Nov;31(11):1717-1732. doi: 10.1038/s41379-018-0093-8. Epub 2018 Jun 28. Mod Pathol. 2018. PMID: 29955146 Free article.
In summary, hairy cell leukemia-variant exhibits a heterogeneous spectrum of clinical, morphologic, immunophenotypic, and genetic features that may overlap with classic hairy cell leukemia and other hairy cell-like B-cell neoplasms. A subset of patients can have an aggressive cli …
In summary, hairy cell leukemia-variant exhibits a heterogeneous spectrum of clinical, morphologic, immunophenotypic, and genetic features t …
Current treatment options in hairy cell leukemia and hairy cell leukemia variant.
Robak T. Robak T. Cancer Treat Rev. 2006 Aug;32(5):365-76. doi: 10.1016/j.ctrv.2006.04.010. Epub 2006 Jun 15. Cancer Treat Rev. 2006. PMID: 16781083 Review.
Hairy cell leukemia (HCL) is a chronic B-cell lymphoproliferative disorder characterized by splenomegaly, pancytopenia and circulating lymphocytes displaying prominent cytoplasmic projections. HCL has usually an indolent course and the patients with asymptomatic disease do …
Hairy cell leukemia (HCL) is a chronic B-cell lymphoproliferative disorder characterized by splenomegaly, pancytopenia and circulating lymph …
Molecular variant of hairy cell leukemia with poor prognosis.
Arons E, Kreitman RJ. Arons E, et al. Leuk Lymphoma. 2011 Jun;52 Suppl 2(Suppl 2):99-102. doi: 10.3109/10428194.2011.565841. Leuk Lymphoma. 2011. PMID: 21599610 Free PMC article.
It was found that VH4-34 was independent from HCLv and a stronger predictor than HCLv in associating with poor prognosis. We conclude that VH4-34+ hairy cell leukemia, which only partly overlaps with HCLv, is associated with poor prognosis after single-agent …
It was found that VH4-34 was independent from HCLv and a stronger predictor than HCLv in associating with poor prognosis. We c …
Mutational Profile in 75 Patients With Anti-Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets.
Castellani F, Visentin A, Schirinzi E, Salvalaggio A, Cacciavillani M, Candiotto C, Baratè C, Cellini A, Bertorelle R, Siciliano G, Trentin L, Briani C. Castellani F, et al. Neurol Neuroimmunol Neuroinflamm. 2023 May 3;10(4):e200122. doi: 10.1212/NXI.0000000000200122. Print 2023 Jul. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37137530 Free PMC article.
DISCUSSION: MYD88(L265P) variant has a high prevalence (66.7%) in anti-MAG antibody neuropathy representing a potential effective mutational target for Bruton tyrosine kinase inhibitors. MYD88(L265P) variant, however, does not seem to be a prognostic factor of neuropathy s …
DISCUSSION: MYD88(L265P) variant has a high prevalence (66.7%) in anti-MAG antibody neuropathy representing a potential effective mutational …
Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia.
Salem DA, Scott D, McCoy CS, Liewehr DJ, Venzon DJ, Arons E, Kreitman RJ, Stetler-Stevenson M, Yuan CM. Salem DA, et al. Cytometry B Clin Cytom. 2019 Jul;96(4):275-282. doi: 10.1002/cyto.b.21785. Epub 2019 May 11. Cytometry B Clin Cytom. 2019. PMID: 31077558 Free PMC article.
HCLv typically lacks these markers, but they may occur in a subgroup of HCL patients with an aggressive clinical course. We examined CD43, CD81, CD79b, and CD200 expression in HCL and HCLv. ...
HCLv typically lacks these markers, but they may occur in a subgroup of HCL patients with an aggressive clinical course. We examined …
Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature.
Visentin A, Imbergamo S, Trimarco V, Pravato S, Romano Gargarella L, Frezzato F, Scapinello G, Bertorelle R, Piva E, Facco M, Semenzato G, Piazza F, Trentin L. Visentin A, et al. Hematol Oncol. 2020 Dec;38(5):823-826. doi: 10.1002/hon.2810. Epub 2020 Oct 11. Hematol Oncol. 2020. PMID: 32979282 Review.
Hairy cell leukemia variant (HCLv) is a provisional disease in the 2016 WHO classification of lymphomas, characterized by unfavorable prognosis and early relapse following conventional purine analog-based regimens. ...
Hairy cell leukemia variant (HCLv) is a provisional disease in the 2016 WHO classification of lymphomas, characterized by unfavorable pro …
VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.
Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. Arons E, et al. Blood. 2009 Nov 19;114(21):4687-95. doi: 10.1182/blood-2009-01-201731. Epub 2009 Sep 10. Blood. 2009. PMID: 19745070 Free PMC article.
Most patients were seeking relapsed/refractory trials, representing a poor-prognosis population. VH4-34, a gene commonly used in autoimmune disorders, was observed in 8 (40%) HCLv and 6 (10%) classic (P = .004) HCL patients. ...
Most patients were seeking relapsed/refractory trials, representing a poor-prognosis population. VH4-34, a gene commonly used in auto …
26 results